For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Intarcia Therapeutics, Inc.

USPTO Granted Patents = 68

% Expired Patents = 29.4

CIPO Patents = 7

EPO Patents = 12

Trademarks = 1

Forward Citations = 1,489

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Catherine Manya Rohloff (24 out of 25 patents)

Pauline C Zamora (19 out of 19 patents)

Thomas R Alessi (18 out of 20 patents)

4. Scott D Lautenbach (15 out of 28 patents)

5. Michael A DesJardin (13 out of 19 patents)

6. Stan Lam (12 out of 12 patents)

7. Ryan D Mercer (9 out of 9 patents)

8. Bing Yang (9 out of 16 patents)

9. Stephen A Berry (8 out of 12 patents)

10. Guohua Chen (7 out of 42 patents)

11. Pedro E De La Serna (7 out of 11 patents)

12. Andrew S Luk (7 out of 14 patents)

13. Jay S Smith (7 out of 7 patents)

14. Michael R Cole (7 out of 28 patents)

15. Paul R Houston (7 out of 13 patents)

Core Competencies:

Osmotic Delivery Systems

Insulinotropic Peptides

Continuous Drug Administration

Implantable Systems

Polypeptides

Suspension Formulations

Therapeutic Methods

Particle Formulations

Flow Modulators

Non-Aqueous Vehicles

Formulation Vehicles

Implant Devices

68 patents: Sort by Forward Citations

1. 12540168 - HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE (2026-02-03),

2. 11739134 - Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use (2023-08-29),

3. 11654183 - Methods comprising continuous administration of exenatide and co-administration of a drug (2023-05-23),

4. D962433 - Implant placement guide (2022-08-30),

5. 11246913 - Suspension formulation comprising an insulinotropic peptide (2022-02-15),

6. 11214607 - Glucagon-receptor selective polypeptides and methods of use thereof (2022-01-04),

7. D933219 - Implant removal tool and assembly (2021-10-12),

8. D912249 - Implant removal tool (2021-03-02),

9. 10925639 - Implant placement and removal systems (2021-02-23),

10. 10869830 - Rapid establishment and/or termination of substantial steady-state drug delivery (2020-12-22),

11. 10835580 - Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug (2020-11-17),

12. 10583080 - Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c (2020-03-10),

13. 10527170 - Osmotic delivery systems and piston assemblies for use therein (2020-01-07),

14. 10501517 - Glucagon-receptor selective polypeptides and methods of use thereof (2019-12-10),

15. 10441528 - Devices, formulations, and methods for delivery of multiple beneficial agents (2019-10-15),

Company Overview

Intarcia Therapeutics, Inc., based in Hayward, California, specializes in innovative osmotic drug delivery systems aimed at transforming the treatment of chronic diseases. The company focuses on the development of implantable systems that facilitate continuous drug administration, particularly utilizing insulinotropic peptides and polypeptides. Their research encompasses advanced therapeutic methods and suspension formulations, positioning Intarcia at the forefront of drug delivery technology and improving patient outcomes through sustained therapeutic interventions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

68 Patents

#6 in Hayward, CA

#1,254 in California

#5,372 in US

#10,888 in the World

Hayward, CA, United States of America

Intarcia Therapeutics, Inc.

Forward Citations = 1,489

58 inventors:

Catherine Manya Rohloff (24 out of 25 patents)

Pauline C Zamora (19 out of 19 patents)

Thomas R Alessi (18 out of 20 patents)

4. Scott D Lautenbach (15 out of 28 patents)

5. Michael A DesJardin (13 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intarcia Therapeutics, Inc.. Retrieved from https://idiyas.com/company/intarcia-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…